Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study Read more
China’s NMPA Approves VYLOY (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Read more
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Bloodstream Infections Read more
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Read more
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US Read more
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Read more